<?xml version="1.0" encoding="UTF-8" standalone="yes"?>

<!-- Copyright (c) 2004-2026 Broad Institute, Inc., Massachusetts Institute of Technology, and Regents of the University of California.  All rights reserved.
     See license terms at www.gsea-msigdb.org/gsea/license_terms_list. Please note that certain gene sets have special access terms.
-->
<MSIGDB BUILD_DATE="Jan 29, 2026" VERSION="2026.1.Hs" NAME="export">
    <GENESET STANDARD_NAME="WANG_RECURRENT_LIVER_CANCER_UP" SYSTEMATIC_NAME="M10922" HISTORICAL_NAMES="" PMID="17975138" AUTHORS="Wang SM,Ooi LL,Hui KM" GEOID="E-MEXP-84,E-TABM-292" EXACT_SOURCE="Fig.3A" GENESET_LISTING_URL="" EXTERNAL_DETAILS_URL="" CHIP="HUMAN_GENE_SYMBOL" CONTRIBUTOR="Yujin Hoshida" CONTRIBUTOR_ORG="Broad Institute" DESCRIPTION_BRIEF="Genes up-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC)." DESCRIPTION_FULL="PURPOSE: To improve the clinical management of human hepatocellular carcinoma (HCC) by accurate identification, at diagnosis, of patients at risk of recurrence after primary treatment for HCC. EXPERIMENTAL DESIGN: Two clinicopathologic variables available at diagnosis, vascular invasion and cirrhosis, together with molecular profiling using Affymetrix human HG-U133A and HG-U133B oligonucleotide probe arrays, were used to identify recurrent HCC disease. RESULTS: HCC patients presented clinically at diagnosis with vascular invasion and cirrhosis showed a high rate (78-83%) of developing recurrent disease within 6 to 35 months. In comparison, most of the HCC patients (80-100%) without vascular invasion and cirrhosis remained disease-free. However, the risk of recurrent disease for HCC patients with either vascular invasion or cirrhosis could not be accurately ascertained. Using a pool of 23 HCC patients with either vascular invasion or cirrhosis as training set, a 57-gene signature was derived and could predict recurrent disease at diagnosis, with 84% (sensitivity 86%, specificity 82%) accuracy, for a totally independent test set of 25 HCC patients with either vascular invasion or cirrhosis. On further analysis, the disease-free rate was significantly different between patients that were predicted to recur or not to recur in the test group (P = 0.002). CONCLUSION: We have presented data to show that by incorporating the status of vascular invasion and cirrhosis available at diagnosis for patients with HCC after partial curative hepatectomy and a novel 57-member gene signature, we could accurately stratify HCC patients with different risks of recurrence." TAGS="" MEMBERS="CETN2,CUL4B,DNAJC10,FAM33A,FLJ11016,KCNK1,LOC159090,MPHOSPH9,PARD3,PTPN11,R3HDM,RACGAP1,RPL10A,SH3GLB2,SMURF2,SSR3,SYNGR2,USH1C,ZBTB38,ZNF652" MEMBERS_SYMBOLIZED="CETN2,CUL4B,DNAJC10,KCNK1,MPHOSPH9,PABIR2,PARD3,PTPN11,R3HDM1,RACGAP1,RBM41,RPL10A,SH3GLB2,SKA2,SMURF2,SSR3,SYNGR2,USH1C,ZBTB38,ZNF652" MEMBERS_EZID="10083,10198,1069,159090,22834,23518,253461,29127,348235,3775,4736,54431,55285,56288,56904,5781,64750,6747,8450,9144" MEMBERS_MAPPING="CETN2,CETN2,1069|CUL4B,CUL4B,8450|DNAJC10,DNAJC10,54431|FAM33A,SKA2,348235|FLJ11016,RBM41,55285|KCNK1,KCNK1,3775|LOC159090,PABIR2,159090|MPHOSPH9,MPHOSPH9,10198|PARD3,PARD3,56288|PTPN11,PTPN11,5781|R3HDM,R3HDM1,23518|RACGAP1,RACGAP1,29127|RPL10A,RPL10A,4736|SH3GLB2,SH3GLB2,56904|SMURF2,SMURF2,64750|SSR3,SSR3,6747|SYNGR2,SYNGR2,9144|USH1C,USH1C,10083|ZBTB38,ZBTB38,253461|ZNF652,ZNF652,22834" FILTERED_BY_SIMILARITY="" FOUNDER_NAMES="" REFINEMENT_DATASETS="" VALIDATION_DATASETS="" CATEGORY_CODE="C2" ORGANISM="Homo sapiens" SUB_CATEGORY_CODE="CGP"/>
</MSIGDB>
